ArticleJACC. Case reports2026
Dysphagia Megalatriensis From Massive Left Atrial Enlargement.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDysphagia megalatriensis, or esophageal compression from a dilated left atrium, is rare and often mistaken for primary esophageal disease. Recognition is crucial, as definitive therapy targets cardiac pathology. CASE SUMMARY: A 63-year-old man with heart failure with reduced ejection fraction, implantable cardioverter-defibrillator placement, and left ventricular thrombus on apixaban presented with progressive dysphagia and weight loss. Given prior esophageal stricture, a barium swallow showed midesophageal narrowing. Upper endoscopy showed extrinsic compression, chest computed tomography showed left atrial enlargement causing esophageal impingement, and echocardiography showed an ejection fraction of 17% with severe left ventricular dilatation, severe mitral and tricuspid regurgitation, and severe pulmonary hypertension. DISCUSSION: Given end-stage biventricular dysfunction, severe valvular disease, and prohibitive surgical risk, the patient was not a candidate for valvular intervention. Management focused on heart failure optimization, dietary modification, and supportive multidisciplinary care. TAKE-HOME MESSAGE: Early recognition prevents unnecessary interventions and shifts focus to supportive strategies in advanced, nonsurgical patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.